Efficacy and safety of liver-specific MRI contrast agents in rats with hepatitis and cirrhosis.
Kato
N
N
Research Department, Nihon Schering K.K., Osaka, Japan.
Takahashi
M
M
Ihara
S
S
Tsujimoto
T
T
Miyazawa
T
T
D000818:Animals; D003287:Contrast Media; D003911:Dextrans; D004195:Disease Models, Animal; D005260:Female; D052203:Ferrosoferric Oxide; D019786:Gadolinium DTPA; D006505:Hepatitis / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D007501:Iron; D008106:Liver Cirrhosis, Experimental / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D009942:Organometallic Compounds; D010087:Oxides; D051381:Rats; D017207:Rats, Sprague-Dawley
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D009942:Organometallic Compounds; D010087:Oxides; C073590:gadolinium ethoxybenzyl DTPA; D007501:Iron; C065507:ferumoxides; D019786:Gadolinium DTPA; D052203:Ferrosoferric Oxide